Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Endocrinology · Autoimmune Polyglandular Syndrome Type 2

The Science of APS-2: Genetics and Diagnosis

At a Glance

Autoimmune Polyglandular Syndrome Type 2 (APS-2) is a condition where the body attacks its own endocrine glands. It is defined by having Addison's disease combined with thyroid disease or Type 1 diabetes, and is confirmed by detecting specific autoantibodies like 21-hydroxylase in your blood.

The biological “engine” behind Autoimmune Polyglandular Syndrome Type 2 (APS-2) is a case of mistaken identity [1]. Your immune system, which is designed to attack invading viruses and bacteria, incorrectly identifies your own endocrine glands as threats and begins an “autoimmune attack” to destroy them [2].

The Genetics of APS-2: A Complex Puzzle

Unlike some genetic conditions caused by a single “broken” gene, APS-2 is polygenic [3]. This means it is caused by the interaction of many different genes combined with environmental triggers [4].

The most important players are the HLA (Human Leukocyte Antigen) genes [3]. These genes provide the instructions for a “labeling system” that helps your immune system tell the difference between your own cells and foreign invaders [5]. In APS-2, certain versions of these genes (specifically types like DR3 and DR4) make the immune system more likely to “mislabel” endocrine tissue as a target [3].

Decoding Your Lab Reports: The Antibody “Hit List”

When doctors suspect APS-2, they look for specific autoantibodies—proteins produced by the immune system that act like “homing beacons” for an attack on specific organs [6]. Knowing which antibodies are present can help predict which glands may be at risk in the future [7].

Target Gland Condition Antibody Name (Abbreviation)
Adrenal Addison’s Disease 21-Hydroxylase (21-OH Ab)
Thyroid Hashimoto’s Thyroid Peroxidase (TPO) or Thyroglobulin (Tg)
Thyroid Graves’ Disease TSH Receptor Antibodies (TRAb) or Thyroid Stimulating Immunoglobulins (TSI)
Pancreas Type 1 Diabetes Pancreatic Autoantibodies: GAD65, IA-2, or ZnT8

Note: The pancreatic autoantibodies like GAD65 (Glutamic Acid Decarboxylase) target specific proteins inside insulin-producing cells. You can test positive for these antibodies years before a gland actually begins to fail [8][6]. This “latent” period is why your care team will recommend regular monitoring of your hormone levels [9].

Differentiating APS-2 from Other Types

There are several types of autoimmune polyglandular syndromes, and knowing the difference helps ensure you receive the correct monitoring and treatment.

  • APS-1 (APECED): This is a very rare, “monogenic” (single-gene) condition caused by a mutation in the AIRE gene [10][11]. It typically starts in childhood and has a “classic triad” of symptoms that are not usually part of APS-2: chronic yeast infections (candidiasis), low calcium levels (hypoparathyroidism), and Addison’s disease [12][13].
  • APS-2 (Schmidt Syndrome): This is defined by having Addison’s disease PLUS either autoimmune thyroid disease or Type 1 diabetes (or both) [1][2]. It typically appears in adults [2].
  • APS-3: This is the most common form [14]. It involves autoimmune thyroid disease paired with another autoimmune condition (like vitiligo or Type 1 diabetes) but crucially does NOT include Addison’s disease [15]. If a patient with APS-3 eventually develops Addison’s disease, their diagnosis is “upgraded” to APS-2.

Understanding these distinctions empowers you to read your lab reports with clarity: in APS-2, the presence of the 21-hydroxylase antibody is the key marker that separates it from APS-3 [1][15].

Common questions in this guide

Is APS-2 a genetic condition?
APS-2 is a polygenic condition, meaning it is caused by an interaction between multiple genes and environmental triggers. The most common genetic factors are the HLA-DR3 and HLA-DR4 genes, which can cause your immune system to mistakenly attack your own endocrine tissue.
Why do doctors test for antibodies if my glands are working normally?
Antibodies can appear in your blood years before an endocrine gland actually begins to fail. Testing for these specific markers allows your care team to predict which glands are at risk and monitor your hormone levels proactively.
What does a positive 21-hydroxylase antibody test mean?
The 21-hydroxylase antibody is a specific protein indicating that your immune system is targeting your adrenal glands. Testing positive for this antibody is a key marker for Addison's disease, which is the defining feature of an APS-2 diagnosis.
What is the difference between APS-2 and APS-3?
The primary difference is the presence of Addison's disease. APS-2 always involves Addison's disease alongside thyroid disease or Type 1 diabetes. APS-3 involves autoimmune thyroid disease and another condition, but crucially does not include Addison's disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific autoantibodies did I test positive for (e.g., 21-hydroxylase, TPO, GAD65)?
  2. 2.Do I have the HLA-DR3 or DR4 genetic markers associated with APS-2?
  3. 3.Since I have one diagnosis, how often will we check for the 'silent' antibodies in my other glands?
  4. 4.Can we review my lab reports to see if my antibody levels are rising or if the glands are already showing signs of decreased function?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Adrenal crisis in a 14-year-old boy 12 years after hematopoietic stem cell transplantation.

    Penger T, Albrecht A, Marx M, et al.

    Endocrinology, diabetes & metabolism case reports 2018; (2018()).

    PMID: 29899990
  2. 2

    Adrenal crisis and autoimmune polyglandular syndromes.

    Freeland ZK, Lueking R, Tsai-Nguyen G, et al.

    Proceedings (Baylor University. Medical Center) 2017; (30(4)):427-428 doi:10.1080/08998280.2017.11930214.

    PMID: 28966452
  3. 3

    From Genetic Predisposition to Molecular Mechanisms of Autoimmune Primary Adrenal Insufficiency.

    Falorni A, Brozzetti A, Perniola R

    Frontiers of hormone research 2016; (46()):115-32 doi:10.1159/000443871.

    PMID: 27211051
  4. 4

    Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature.

    Pan Q, Li P

    Frontiers in immunology 2024; (15()):1366335 doi:10.3389/fimmu.2024.1366335.

    PMID: 38707904
  5. 5

    Polyglandular syndrome type 2 in a Mexican family and its association with human leukocyte antigen.

    Bermeo-Cabrera J, Reza-Albarrán AA, Granados J, et al.

    Clinical case reports 2019; (7(1)):79-82 doi:10.1002/ccr3.1919.

    PMID: 30656013
  6. 6

    Adrenocortical Crisis Triggered by Levothyroxine in an Unrecognized Autoimmune Polyglandular Syndrome Type-2: A Case Report with Review of the Literature.

    Patel DM, Gurumikhani JK, Patel MV, et al.

    Current drug safety 2021; (16(1)):101-106 doi:10.2174/1574886315666200826095842.

    PMID: 32851966
  7. 7

    Autoimmune polyglandular syndrome type 2: A case report.

    Bakkour A, Zakkor MD, Taha Khairy L, et al.

    Annals of medicine and surgery (2012) 2022; (78()):103742 doi:10.1016/j.amsu.2022.103742.

    PMID: 35600201
  8. 8

    Adolescent onset of autoimmune polyglandular syndrome type 2.

    Murphy SA, Mohd Din FH, O'Grady MJ

    BMJ case reports 2022; (15(5)) doi:10.1136/bcr-2022-249839.

    PMID: 35606028
  9. 9

    The "polyglandular crisis" behind recurrent hyponatremia: misdiagnosis of a case of autoimmune polyglandular syndrome type 2 and clinical lessons learned.

    Yan M, Wu H, Deng J, et al.

    Frontiers in immunology 2026; (17()):1744295 doi:10.3389/fimmu.2026.1744295.

    PMID: 41659856
  10. 10

    APECED and the place of AIRE in the puzzle of the immune network associated with autoimmunity.

    Aytekin ES, Cagdas D

    Scandinavian journal of immunology 2023; (98(2)):e13299 doi:10.1111/sji.13299.

    PMID: 38441333
  11. 11

    Exploring Chronic Hypocalcemia: Insights into Autoimmune Polyglandular Syndrome Type 1-A Case Study and Literature Review.

    Brad GF, Nicoară DM, Scutca AC, et al.

    Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082368.

    PMID: 38673639
  12. 12

    Chronic Mucocutaneous Candidiasis in Autoimmune Polyendocrine Syndrome Type 1.

    Humbert L, Cornu M, Proust-Lemoine E, et al.

    Frontiers in immunology 2018; (9()):2570 doi:10.3389/fimmu.2018.02570.

    PMID: 30510552
  13. 13

    Early-onset Chronic Keratitis as the First Presenting Component of Autoimmune Polyendocrine Syndrome Type 1: A Case Report and Review of the Literature

    Şimşek E, Şimşek T, Çilingir O

    Journal of clinical research in pediatric endocrinology 2025; (17(3)):359-364 doi:10.4274/jcrpe.galenos.2023.2023-9-17.

    PMID: 38084036
  14. 14

    Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy.

    Betterle C, Furmaniak J, Sabbadin C, et al.

    Journal of endocrinological investigation 2023; (46(4)):643-665 doi:10.1007/s40618-022-01994-1.

    PMID: 36609775
  15. 15

    A Patient with Fulminant Myasthenia Gravis Is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3.

    Inoue H, Yamada K, Fujii A, et al.

    Internal medicine (Tokyo, Japan) 2020; (59(17)):2177-2181 doi:10.2169/internalmedicine.4708-20.

    PMID: 32461531

This page explains the genetics and diagnostic markers of APS-2 for educational purposes only. Always consult your endocrinologist for help interpreting your specific lab results and autoantibody tests.

Get notified when new evidence is published on Autoimmune polyendocrinopathy type 2.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.